TABLE 2.

Adverse events reported in at least 2 participants

	Total	Group A	Group B
Adverse event, n (%)	n = 13	n = 6	n = 7
Nausea	8 (61.5)	4 (66.7)	4 (57.1)
Anemia	3 (23.1)	1 (16.7)	2 (28.6)
Fatigue	3 (23.1)	3 (50)	0 (0)
Headache	3 (23.1)	2 (33.3)	1 (14.3)
Paresthesia	3 (23.1)	2 (33.3)	1 (14.3)
Platelet count decreased	3 (23.1)	0 (0)	3 (42.9)
Cough	2 (15.4)	1 (16.7)	1 (14.3)
Diarrhea	2 (15.4)	1 (16.7)	1 (14.3)
Dry mouth	2 (15.4)	1 (16.7)	1 (14.3)
Gastroesophageal reflux disease	2 (15.4)	1 (16.7)	1 (14.3)
Myalgia	2 (15.4)	0 (0)	2 (28.6)
Neutrophil count decreased	2 (15.4)	1 (16.7)	1 (14.3)
Pain	2 (15.4)	1 (16.7)	1 (14.3)
Thromboembolic event	2 (15.4)	0 (0)	2 (28.6)
Upper respiratory infection	2 (15.4)	1 (16.7)	1 (14.3)
Vomiting	2 (15.4)	0 (0)	2 (28.6)